

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/749,778	12/28/2000	Ranju Ralhan	041144F005	4846
7	7590 08/05/2002			
Smith, Gambrell & Russell, LLP Beveridge, DeGrandi, Weilacher & Young Intellectual Property Group			EXAMINER	
			SAKELARIS, SALLY A	
1850 M Street, N.W., Suite 800 Washington, DC 20036			ART UNIT	PAPER NUMBER
			1634	
			DATE MAILED: 08/05/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s)					
Office Action Symmetry	09/749,778	RALHAN, RANJU				
Office Action Summary	Examiner	Art Unit				
	Sally A Sakelaris	1634				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1) Responsive to communication(s) filed on	_·					
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims						
4)⊠ Claim(s) <u>1-16</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-16 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informa	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/749,778

Art Unit: 1634

## RESTRICTION

- 1. Restriction to one of the following inventions is required under 35 U.S.C. §121:
- I. Claim 1 is drawn to a single nucleotide polymorphism, classified in Class 435, subclass 6.
- II. Claims 2-7 and 13-16 are drawn to a method for screening by genotyping through PCR with nucleic acids, classified in Class 435, subclass 91.2.
- III. Claim 8 is drawn to a method of detecting a variant protein, classified in Class 530, subclass 300 and 350.
- IV. Claims 9 and 10 are drawn to a method of pre-screening through peptide binding assays, classified in Class 435, subclass 7.1.
- V. Claims 11 and 12 are drawn to a method of regulating expression and identifying drug targets by measuring in vitro transcription of nucleic acids, classified in Class 514, subclass 44.
- 2. The inventions are distinct, each from the other because of the following reasons:
- a. Inventions I and III and I and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions and are not disclosed as capable of use together because the nucleic acids of invention I are not required to practice the methods of inventions III and IV involving polypeptides.

Application/Control Number: 09/749,778

Art Unit: 1634

b. Inventions I and II and I and V, are related as products and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the nucleic acid of invention I can be used in a materially different process such as for protein synthesis.

- c. Inventions II and III, II and IV, III and V, III and IV, III and V, and IV and V are drawn to patentably distinct methods which involve different method steps, include different reagents and have different objectives. Invention II involves screening by genotyping through PCR with nucleic acids. The invention of Group III is drawn to a method of detecting a variant protein. Group IV is drawn to a method of pre-screening involving the use of peptide binding assays. Group V is drawn to a method of regulating expression by measuring the transcription of nucleic acids. The methods all have different method steps, objectives and reagents. Therefore the methods are distinct over one another.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by the different classifications and their divergent subject matter and because these inventions require different searches that are not co-extensive, examination of these distinct inventions would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the reply to this requirement, to be complete, must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/749,778

Art Unit: 1634

5. Any inquiry concerning this communication or earlier communication from the examiner should be directed to Sally Sakelaris whose telephone number is (703) 306-0284. The examiner can normally be reached on Monday-Friday from 8:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W.Gary Jones, can be reached on (703)308-1152. The fax number for the Technology Center is (703)305-3014 or (703)305-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to Chantai Dessau whose telephone number is (703)605-1237.

Sally Sakelaris

20000 XI

LISA B. ARTHUR
PRIMARY EXAMINER
GROUP 1800 1 (200)

Loab. alle